Brian Park, PharmD

Drug Information Specialist https://www.clinicaladvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Gastroenterology Information Center

Clinical Remission Observed With Risankizumab in Crohn Disease Trials

Brian Park, PharmD

January 12, 2021

Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.

Oncology Information Center

Opdivo No Longer FDA-Approved for Small Cell Lung Cancer

Brian Park, PharmD

January 12, 2021

In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.

Vaccine Information Center

Vaccine Candidate AZD1222 Effective Against COVID-19

Brian Park, PharmD

November 23, 2020

A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.

Infectious Diseases Information Center

NIH: Hydroxychloroquine Not Effective for COVID-19

Brian Park, PharmD

November 13, 2020

The ORCHID trial was halted in June 2020 after a data and safety monitoring board determined that hydroxychloroquine was unlikely to benefit hospitalized patients.

Dermatology Information Center

FDA Approves Rx-to-OTC Switch of Sklice for Head Lice Treatment

Brian Park, PharmD

November 2, 2020

Each gram of lotion contains 5mg of ivermectin, the same as the prescription strength.

Infectious Diseases Information Center

Lilly to Supply Bamlanivimab to US Government Pending EUA Decision

Brian Park, PharmD

October 30, 2020

Bamlanivimab is a potent neutralizing IgG1 monoclonal antibody directed against the spike protein of severe acute respiratory syndrome coronavirus 2.

Neurology Information Center

FDA Rejects Qtrypta NDA for Acute Treatment of Migraine

Brian Park, PharmD

October 29, 2020

Qtrypta delivers zolmitriptan, a selective 5-HT1B/1D receptor agonist, using the Company’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology that consists of a drug-coated microneedle patch.

Vaccine Information Center

Moderna: 30,000 Participants Enrolled in COVID-19 Vaccine Trial

Brian Park, PharmD

October 28, 2020

The trial is investigating the efficacy, safety, and immunogenicity of mRNA-1273 at the 100mcg dose.

Allergy and Immunology Information Center

Novel Pneumococcal Conjugate Vaccine Immunogenic in Phase 3 Trials

Brian Park, PharmD

October 26, 2020

Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.

Infectious Diseases Information Center

FDA Approves Veklury as First Treatment for COVID-19

Brian Park, PharmD

October 23, 2020

The FDA approved Veklury (remdesivir; Gilead Sciences) for the treatment of COVID-19 in patients aged ≥12 years (weighing ≥40kg) requiring hospitalization.

Next post in Infectious Diseases Information Center